The stock popped after the company reported a solid quarter of operations, but serious red flags remain.
News & Analysis: Vanda Pharmaceuticals
Sales of Hetlioz and Fanapt are exceeding expectations.
VNDA earnings call for the period ending June 30, 2019.
Revenue from the company's two drug products decreased 10% from the fourth quarter of 2018.
VNDA earnings call for the period ending March 31, 2019.
The S&P 500 has rarely been more expensive than it is today. That doesn't mean bargain-hunting investors are out of luck.
This high-octane midstream stock, drug developer, and retail giant have the growth potential to send their shares skyward.
Two down-on-their-luck growth stocks are worth a closer look after a poor start to 2019.
Investors looking to inject growth into their portfolios should give these companies a closer look.
The pharma company reported fourth-quarter and full-year 2018 operating results.